Treatment Side Effects
0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Martin PharmaceuticalsNY - New York
1 programthe Mandarin Version of the electronic patient self-Reporting of Adverse-eventsN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
EppendorfTumor removal
Martin Pharmaceuticalsthe Mandarin Version of the electronic patient self-Reporting of Adverse-events
Clinical Trials (2)
Total enrollment: 440 patients across 2 trials
Surgery Versus Endoscopic Resection for Incompletely Removed Early Colon CAnceR
Start: Oct 2023Est. completion: Sep 2033304 patients
N/ARecruiting
NCT05446051Martin Pharmaceuticalsthe Mandarin Version of the electronic patient self-Reporting of Adverse-events
Development and Testing of a TTDSS for Cancer Patients
Start: Jul 2022Est. completion: Apr 2024136 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 440 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.